IDH2 and central nervous system cancer: In addition to the prognostic importance of the IDH-mutation status for glioma patients, recent PET studies suggest that within patients with molecularly defined gliomas the further identification of patients with an additional survival benefit using dynamic FET PET parameters is possible [18, 26, 27].